Evidence map›Paper›PMID 38921449›Full record

ReviewMetabolites2024

Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer.

Muhammad Usman Babar, Ala F Nassar, Xinxin Nie, Tianxiang Zhang, Jianwei He, Jacky Yeung, Paul Norris, Hideki Ogura, Anne Muldoon, Lieping Chen and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metabolites, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Muhammad Usman BabarDepartment of Pathology, Yale University, New Haven, CT 06520, USA.
Ala F NassarDepartment of Immunobiology, Yale University, West Haven, CT 06520, USA.
Xinxin NieDepartment of Immunobiology, Yale University, West Haven, CT 06520, USA.
Tianxiang ZhangDepartment of Immunobiology, Yale University, West Haven, CT 06520, USA.
Jianwei HeDepartment of Immunobiology, Yale University, West Haven, CT 06520, USA.ORCID 0009-0009-9809-9400
Jacky YeungDepartment of Immunobiology, Yale University, West Haven, CT 06520, USA.
Paul NorrisSciex, 500 Old Connecticut Path, Framingham, MA 01701, USA.
Hideki OguraDepartment of Microbiology, Hyogo Medical University, Kobe 678-1297, Japan.
Anne MuldoonDepartment of Immunobiology, Yale University, West Haven, CT 06520, USA.
Lieping ChenDepartment of Immunobiology, Yale University, West Haven, CT 06520, USA.
Stephania LibrerosDepartment of Pathology, Yale University, New Haven, CT 06520, USA.ORCID 0000-0002-2973-5014

Funding

Bone Marrow Functions of Novel Pro-Resolving MediatorsR00HL153673 · NHLBI · YALE UNIVERSITY · PI LIBREROS, STEPHANIA · 2023 to 2025
$747k
NHLBI NIH HHS R00 HL153673
6 · The paper itself

Abstract

Acute inflammation is the body's first defense in response to pathogens or injury that is partially governed by a novel genus of endogenous lipid mediators that orchestrate the resolution of inflammation, coined specialized pro-resolving mediators (SPMs). SPMs, derived from omega-3-polyunstaturated fatty acids (PUFAs), include the eicosapentaenoic acid-derived and docosahexaenoic acid-derived Resolvins, Protectins, and Maresins. Herein, we review their biosynthesis, structural characteristics, and therapeutic effectiveness in various diseases such as ischemia, viral infections, periodontitis, neuroinflammatory diseases, cystic fibrosis, lung inflammation, herpes virus, and cancer, especially focusing on therapeutic effectiveness in respiratory inflammation and ischemia-related injuries. Resolvins are sub-nanomolar potent agonists that accelerate the resolution of inflammation by reducing excessive neutrophil infiltration, stimulating macrophage functions including phagocytosis, efferocytosis, and tissue repair. In addition to regulating neutrophils and macrophages, Resolvins control dendritic cell migration and T cell responses, and they also reduce the pro-inflammatory cytokines, proliferation, and metastasis of cancer cells. Importantly, several lines of evidence have demonstrated that Resolvins reduce tumor progression in melanoma, oral squamous cell carcinoma, lung cancer, and liver cancer. In addition, Resolvins enhance tumor cell debris clearance by macrophages in the tumor's microenvironment. Resolvins, with their unique stereochemical structure, receptors, and biosynthetic pathways, provide a novel therapeutical approach to activating resolution mechanisms during cancer progression.

Indexed as

cancerdocosahexaenoic acidefferocytosisischemialipid mediatorsresolutionrespiratory inflammation

Identifiers

PMID38921449
PMCPMC11205484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.